Abstract IA003: ctDNA Guiding adjuvant treatment in early stage colon cancer: Are we moving the needle?


 My presentation will summarize the accumulating evidence on the ability of circulating tumor DNA to detect minimal residual disease and track adjuvant treatment efficacy in colorectal cancer and the potential for ctDNA to reshape the adjuvant treatment paradigm. I will also discuss the rationale and results of the DYNAMIC trial (ctDNA-guiding adjuvant therapy study in stage II colon cancer) and other ongoing ctDNA-based trials.
 Citation Format: Jeanne Tie. ctDNA Guiding adjuvant treatment in early stage colon cancer: Are we moving the needle? [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer; 2022 Oct 1-4; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;82(23 Suppl_1):Abstract nr IA003.